116 results on '"Naqvi, Syed Arsalan Ahmed"'
Search Results
2. Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis
3. First-line (1L) systemic therapy in locally advanced/metastatic urothelial cancer (Ia/mUC): A living interactive systematic review and network meta-analysis.
4. Efficacy of first line (1L) poly ADP-ribose polymerase inhibitors (PARPi) in combination with androgen pathway inhibitors (API) by homologous recombination repair (HRR) genes in metastatic castration-resistant prostate cancer (mCRPC): A living meta-analysis.
5. Stratified absolute benefit with adjuvant immunotherapy (aIO) in muscle-invasive bladder cancer (MIBC): A meta-analysis.
6. Disparities in Representation of Women, Older Adults, and Racial/Ethnic Minorities in Immune Checkpoint Inhibitor Trials
7. Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis
8. Accuracy of pre-operative parameters in predicting severe cholecystitis-A systematic review
9. Secondary primary malignancies among patients with GU cancer.
10. A cost-effectiveness analysis assessing systemic treatments in metastatic castration-sensitive prostate cancer (mCSPC) by volume of disease.
11. Clinical efficacy of enfortumab-pembrolizumab combination therapy in locally advanced/metastatic urothelial carcinoma (UC): A real-world experience.
12. A meta-analysis assessing objective response rates with first-line systemic treatment options in locally advanced/metastatic urothelial carcinoma.
13. Enfortumab vedotin treatment regimens and efficacy in urothelial carcinoma: The Mayo Clinic experience.
14. Clinical efficacy of lurbinectedin in metastatic neuroendocrine carcinomas of the genitourinary tract: Multi-institutional real-world experience.
15. Health-related quality of life (HrQoL) of first-line treatments in metastatic renal cell carcinoma (mRCC): A network meta-analysis.
16. Risk of suicide-related deaths (SRD) among patients diagnosed with metastatic genitourinary (mGU) cancers: A retrospective cohort study.
17. Risk of early non-cancer deaths in adults diagnosed with metastatic genitourinary (mGU) cancers: A retrospective cohort study.
18. First-line PARP inhibitors (PARPi) with androgen receptor pathway inhibitors (ARPi) in metastatic castration-resistant prostate cancer (mCRPC): A systematic review and meta-analysis.
19. Comparative survival in metastatic castration-sensitive prostate cancer (mCSPC) by prognostic subgroups: A living network meta-analysis.
20. Comparative health-related quality of life (QoL) in metastatic castration-sensitive prostate cancer (mCSPC): A living systematic review.
21. Comparative Effectiveness of Anticoagulants in Patients With Cancer-Associated Thrombosis
22. Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis
23. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer
24. Deep prostate-specific antigen response and overall survival in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
25. Pathologic response with neoadjuvant chemotherapy, immunotherapy, and chemo-immunotherapy for muscle-invasive bladder cancer (MIBC): A systematic review and meta-analysis.
26. Adjuvant immunotherapy in renal cell carcinoma: A living systematic review and network meta-analysis (NMA).
27. Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis.
28. Socioeconomic vulnerability and the risk of genitourinary cancer mortality among United States counties.
29. Efficacy of immune-checkpoint inhibitor (ICI) combination as a first-line (1L) therapy in metastatic renal cell carcinoma (mRCC) with sarcomatoid histology: A systematic review and meta-analysis.
30. Source of funding and enrollment disparity in prostate cancer (PCa) clinical trials.
31. A living interactive systematic review and network meta-analysis evaluating systemic therapies in metastatic castration-sensitive prostate cancer (mCSPC).
32. Source of funding and enrollment disparities in the inclusion of minorities in colorectal clinical trials: A systematic review and meta-analysis.
33. Social vulnerability and gastrointestinal cancer mortality among United States counties.
34. Disparities in the Inclusion of Racial and Ethnic Minority Groups and Older Adults in Prostate Cancer Clinical Trials
35. Post Autologous Stem Cell Transplant Maintenance in Patients with Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis
36. The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate
37. Quantifying the absolute benefit of neoadjuvant chemotherapy followed by definitive therapy in patients with muscle-invasive bladder cancer: A systematic review and meta-analysis.
38. Indirect comparisons of triplet therapy as compared to novel hormonal therapy doublets in patients with metastatic castration sensitive prostate cancer.
39. Anti-CD19 chimeric antigenic receptor T cell as a second-line therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.
40. Real-world utilization and comparative effectiveness of treatment options in cancer-associated thrombosis: A propensity score weighed analysis.
41. Treatment of cancer associated thrombosis: A living interactive systematic review and bayesian network meta-analysis.
42. A systematic review and network meta-analysis evaluating neoadjuvant treatments in muscle-invasive bladder cancer.
43. Quantifying absolute benefit of adjuvant treatments in renal cell carcinoma: A systematic review and network-meta-analysis.
44. Differential efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with DNA repair defects: A systematic review and meta-analysis.
45. A quantitative synthesis of disparities in the inclusion of racial/ethnic minorities and older adults in prostate cancer clinical trials over the last three decades.
46. Triplet therapy in metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
47. Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer.
48. First-line treatment options in metastatic castration-sensitive prostate cancer: A systematic review and network meta-analysis.
49. Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis
50. A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.